JP2024508545A5 - - Google Patents

Info

Publication number
JP2024508545A5
JP2024508545A5 JP2023553660A JP2023553660A JP2024508545A5 JP 2024508545 A5 JP2024508545 A5 JP 2024508545A5 JP 2023553660 A JP2023553660 A JP 2023553660A JP 2023553660 A JP2023553660 A JP 2023553660A JP 2024508545 A5 JP2024508545 A5 JP 2024508545A5
Authority
JP
Japan
Application number
JP2023553660A
Other languages
Japanese (ja)
Other versions
JP2024508545A (ja
JPWO2022183287A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2022/050295 external-priority patent/WO2022183287A1/en
Publication of JP2024508545A publication Critical patent/JP2024508545A/ja
Publication of JP2024508545A5 publication Critical patent/JP2024508545A5/ja
Publication of JPWO2022183287A5 publication Critical patent/JPWO2022183287A5/ja
Pending legal-status Critical Current

Links

JP2023553660A 2021-03-02 2022-03-02 セロトニン作動性薬に関係する障害の治療に有用なセロトニン作動性薬としてのインドール誘導体 Pending JP2024508545A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163155634P 2021-03-02 2021-03-02
US63/155,634 2021-03-02
PCT/CA2022/050295 WO2022183287A1 (en) 2021-03-02 2022-03-02 Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto

Publications (3)

Publication Number Publication Date
JP2024508545A JP2024508545A (ja) 2024-02-27
JP2024508545A5 true JP2024508545A5 (https=) 2025-03-04
JPWO2022183287A5 JPWO2022183287A5 (https=) 2025-03-04

Family

ID=83153685

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023553664A Pending JP2024508922A (ja) 2021-03-02 2022-03-02 セロトニン作動性薬に関係する障害の治療に有用なセロトニン作動性薬としてのインドール誘導体
JP2023553660A Pending JP2024508545A (ja) 2021-03-02 2022-03-02 セロトニン作動性薬に関係する障害の治療に有用なセロトニン作動性薬としてのインドール誘導体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2023553664A Pending JP2024508922A (ja) 2021-03-02 2022-03-02 セロトニン作動性薬に関係する障害の治療に有用なセロトニン作動性薬としてのインドール誘導体

Country Status (11)

Country Link
US (2) US20240166630A1 (https=)
EP (2) EP4301730A4 (https=)
JP (2) JP2024508922A (https=)
KR (2) KR20230154220A (https=)
CN (2) CN117500788A (https=)
AU (2) AU2022229037A1 (https=)
BR (1) BR112023017754A2 (https=)
CA (2) CA3210275A1 (https=)
IL (2) IL305622A (https=)
MX (2) MX2023010316A (https=)
WO (2) WO2022183287A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240096817A (ko) 2020-05-19 2024-06-26 사이빈 아이알엘 리미티드 중수소화된 트립타민 유도체 및 사용 방법
KR20250053871A (ko) * 2022-08-31 2025-04-22 사이빈 아이알엘 리미티드 트립타민 화합물, 조성물, 및 사용 방법
US12396981B2 (en) 2023-03-09 2025-08-26 William Shulman Methods of using DMT
CN121752545A (zh) * 2023-11-06 2026-03-27 宜昌人福药业有限责任公司 一种n,n-二甲基色胺衍生物及其药物组合物、制备方法和用途
WO2025104490A1 (en) * 2023-11-14 2025-05-22 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto
WO2025104491A1 (en) * 2023-11-14 2025-05-22 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578612A (en) * 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
PL170330B1 (pl) * 1990-10-15 1996-11-29 Pfizer Sposób wytwarzania nowych pochodnych indolu PL PL PL PL PL PL
DE60222396T2 (de) * 2001-03-29 2008-05-15 Eli Lilly And Co., Indianapolis N-(2-arylethyl) benzylamine als 5-ht6 rezeptor-antagoniste
TWI318621B (en) * 2006-08-03 2009-12-21 Nat Bureau Of Controlled Drugs Dept Of Health A series of deuterium labelled compounds as drug testing standards and their preparations
US20090062367A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched eletriptan
EP2753605B1 (en) * 2011-09-09 2019-03-27 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
US20190358238A1 (en) * 2016-11-16 2019-11-28 University Of South Florida ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES
EP4219498A1 (en) * 2019-03-07 2023-08-02 Arbormentis LLC Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic / psychotomimetic dosages and formulations
GB201907871D0 (en) * 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
PH12022551981A1 (en) * 2020-02-04 2023-10-16 Mindset Pharma Inc Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders
MX2022009528A (es) * 2020-02-04 2022-11-14 Mindset Pharma Inc Derivados de 3-pirrolidina-indol como agentes psicodélicos serotoninérgicos para el tratamiento de trastornos del snc.
TW202144369A (zh) * 2020-04-26 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 海鞘素類衍生物及其製備方法與醫藥用途
WO2021234608A1 (en) * 2020-05-19 2021-11-25 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
KR20240096817A (ko) * 2020-05-19 2024-06-26 사이빈 아이알엘 리미티드 중수소화된 트립타민 유도체 및 사용 방법

Similar Documents

Publication Publication Date Title
BR102022025291A2 (https=)
BR102023014872A2 (https=)
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR102022023461A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
BY13149U (https=)
BY13159U (https=)
BY13140U (https=)
BY13141U (https=)
BY13142U (https=)
BY13143U (https=)
BY13144U (https=)
BY13145U (https=)
BY13176U (https=)